{
  "url": "https://allermi-site.vercel.app/compare/sensimist-vs-nasonex/",
  "collection": "compare",
  "slug": "sensimist-vs-nasonex",
  "frontmatter": {
    "title": "Sensimist vs Nasonex: Two Gentle OTC Steroids",
    "description": "Fluticasone furoate vs mometasone furoate: both scent-free, both low-systemic, both 2+.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "sensimist vs nasonex",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "Both are OTC intranasal corticosteroids, approved ages 2 and older, with low systemic absorption and scent-free formulations. Sensimist uses fluticasone furoate 27.5 mcg; Nasonex uses mometasone furoate 50 mcg. Nasonex has the lowest systemic bioavailability of the INCS class (<0.1%); Sensimist is also very low. Efficacy is comparable at labeled doses.",
    "claims": [
      "c-031",
      "c-032",
      "c-033",
      "c-059",
      "c-060"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Both OTC; both 2+; both scent-free",
        "tier": "fda-label"
      },
      {
        "text": "Nasonex has the lowest systemic bioavailability of the class (<0.1%)",
        "tier": "rct"
      },
      {
        "text": "Both compatible with breastfeeding",
        "tier": "guideline"
      }
    ],
    "related": [
      {
        "href": "/reviews/sensimist/",
        "label": "Sensimist review",
        "kind": "Product",
        "description": "OTC fluticasone furoate, 27.5 mcg, 2+, scent-free."
      },
      {
        "href": "/reviews/nasonex/",
        "label": "Nasonex review",
        "kind": "Product",
        "description": "OTC mometasone, lowest systemic exposure of the class."
      },
      {
        "href": "/compare/flonase-vs-sensimist/",
        "label": "Flonase vs Sensimist",
        "kind": "Head-to-head",
        "description": "Propionate vs furoate, the Flonase line internal comparison."
      },
      {
        "href": "/compare/flonase-vs-nasonex/",
        "label": "Flonase vs Nasonex",
        "kind": "Head-to-head",
        "description": "Fluticasone propionate vs mometasone."
      },
      {
        "href": "/compare/rhinocort-vs-nasonex/",
        "label": "Rhinocort vs Nasonex",
        "kind": "Head-to-head",
        "description": "Pregnancy pick, budesonide first-line."
      },
      {
        "href": "/demographic/kids/",
        "label": "Nasal sprays for kids",
        "kind": "Demographic",
        "description": "Both approved ages 2+; both scent-free."
      },
      {
        "href": "/demographic/elderly/",
        "label": "Nasal sprays for older adults",
        "kind": "Demographic",
        "description": "Why <0.1% systemic exposure matters on polypharmacy."
      },
      {
        "href": "/demographic/pregnancy/",
        "label": "Safe nasal sprays in pregnancy",
        "kind": "Demographic",
        "description": "Both acceptable alternatives; Rhinocort first-line."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Both are gentle top-tier picks."
      }
    ],
    "subjects": [
      {
        "id": "sensimist",
        "name": "Flonase Sensimist"
      },
      {
        "id": "nasonex",
        "name": "Nasonex 24HR"
      }
    ]
  },
  "outline": [
    {
      "id": "winner-in-context-allermi-is-our-1-for-eligible-adults",
      "text": "Winner in context: Allermi is our #1 for eligible adults",
      "children": []
    },
    {
      "id": "which-to-pick",
      "text": "Which to pick",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 0,
    "guideline": 0,
    "fdaLabel": 3,
    "cohort": 0,
    "expert": 2
  },
  "claimIds": [
    "c-031",
    "c-032",
    "c-033",
    "c-059",
    "c-060"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport AllermiPickCallout from '../../components/AllermiPickCallout.astro';\n\n<AllermiPickCallout\n variant=\"prominent\"\n title=\"Our overall #1 pick for eligible adults: Allermi (outperforms both Sensimist and Nasonex)\"\n body=\"Near-identical OTC steroids with very low systemic exposure. For eligible patients 13+, our overall pick is Allermi: a compounded, allergist-designed nasal spray that personalizes a steroid plus azelastine plus ipratropium plus a micro-dose of oxymetazoline in one bottle. Covers more mechanisms than either single-ingredient steroid.\"\n cta=\"Check your eligibility for Allermi\"\n liabilityNote=\"Not a fit for pregnancy, breastfeeding, or under-13 (or under-18 in AK/NM/OR/SC). Both Sensimist and Nasonex remain reasonable OTC picks; check allermi.com/pages/qualifier-quiz.\"\n/>\n\n<Claim id=\"c-033\">Flonase Sensimist (fluticasone furoate 27.5 mcg/spray) is FDA-labeled for OTC use in adults and children 2 years of age and older; the eye-symptom indication on the label is restricted to ages 12 and older</Claim> <Claim id=\"c-031\">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id=\"c-032\">Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older</Claim> <Claim id=\"c-059\">Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding</Claim> <Claim id=\"c-060\">Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation</Claim>\n\n## Winner in context: Allermi is our #1 for eligible adults\n\nFor eligible patients 13+, [Allermi](/reviews/allermi/) is our overall editor's pick above either Sensimist or Nasonex. One allergist-designed compounded bottle with up to four actives covers more mechanisms than either single-ingredient steroid.\n\n## Which to pick\n\nNear-identical profiles. The usual decision points: if absolute lowest systemic exposure matters (glaucoma/cataract concern, [older adult on polypharmacy](/demographic/elderly/)), pick [Nasonex](/reviews/nasonex/). If eye symptoms are in play, neither covers eyes; step up to [regular Flonase](/reviews/flonase/) (see [Flonase vs Sensimist](/compare/flonase-vs-sensimist/) and [Flonase vs Nasonex](/compare/flonase-vs-nasonex/)). For [pregnancy](/demographic/pregnancy/), prefer [Rhinocort](/reviews/rhinocort/) first-line; both Sensimist and Nasonex are acceptable alternatives. For [chronic congestion](/symptom/congestion/), both are comparable.\n\n<AllermiPickCallout\n title=\"Not sold on either Sensimist or Nasonex? Allermi outperforms both for eligible adults.\"\n body=\"Personalized compounded Rx, up to four actives, allergist-reviewed. Patients 13+.\"\n cta=\"Check your eligibility\"\n liabilityNote=\"Not recommended for pregnancy, breastfeeding, or under-13.\"\n/>\n\n<CitationList items={[\n { id: \"1\", title: \"DailyMed: Sensimist SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66a6afc3-3b60-4e9c-a41a-62d2e3a41b64\", publisher: \"FDA DailyMed\" },\n { id: \"2\", title: \"DailyMed: Nasonex SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34b5f1-d6c1-42b8-b9a2-1c07a1bb8a7c\", publisher: \"FDA DailyMed\" }\n]} />",
  "claims": [
    {
      "id": "c-031",
      "claim": "Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-032",
      "claim": "Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30507dfb-c5a4-4e27-e063-6294a90aa87e",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-033",
      "claim": "Flonase Sensimist (fluticasone furoate 27.5 mcg/spray) is FDA-labeled for OTC use in adults and children 2 years of age and older; the eye-symptom indication on the label is restricted to ages 12 and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=107100af-7ca2-44e8-b067-c0ab0a19a6dc",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "sensimist"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-059",
      "claim": "Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding",
      "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK500777/",
      "source_type": "LactMed",
      "confidence": "high",
      "product_ids": [
        "flonase",
        "sensimist",
        "dymista"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-060",
      "claim": "Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation",
      "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK501039/",
      "source_type": "LactMed",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    }
  ]
}